Ipriflavone (Osteofix) (Osteofix) is a feed additive and a catabolic agent. It is used to inhibit bone resorption.

Ipriflavone significantly inhibits the growth of MDA-231 xenograft tumors; treated mice exhibited a reduction in tumor volume by 25% and 45% and a decrease in weight by 47% and 63% compared to the control group, respectively, along with extended survival times of the tumor-bearing mice. Additionally, oral administration of 12 mg of Ipriflavone markedly suppressed the development of osteolytic metastases in bone metastatic cancer, impeded the progression of osteolytic lesions, and reduced the number of osteoclasts adjacent to cancer cells.

Ipriflavone modulates the differentiation and biosynthesis of human bone marrow stromal osteoprogenitor cells (BMCs) by enhancing the expression of certain key matrix proteins and promoting mineralization. In cultured murine undifferentiated osteoblasts, 10 mM Ipriflavone significantly inhibits bone resorption augmented by glycation end products. At a 50 mM dose, Ipriflavone does not induce apoptosis in MDA-231 cells. Additionally, Ipriflavone exhibits a dose-dependent inhibition of MDA-231 cell proliferation and DNA synthesis and impedes ligand-induced phosphorylation of Tyr845 in the EGFR.

Cells are exposed to various concentrations of Ipriflavone for 24, 48, 72 and 96 hours. Cells are treated with trypan blue to estimate the number of viable cells. For thymidine incorporation analysis, [3H]Thymidine (1 μCi) is added, and cells are harvested onto glass fiber filters 4 hours later. Radioactivity is determined by scintillation counting.(Only for Reference)